MySmallCap

We want to welcome @Geovax_News to the @ROTHCapital Partners 3rd Annual Healthcare Opportunities Conference October 9th. See their profile on @B2iDigital at b2idigital.com/3rd-annual-ro… GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and therapy for advanced head and neck cancer. Additional development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, and Marburg), malaria and Zika virus, as well as therapies for various solid tumors. (Source: Company Website 08.06.24) We look forward to seeing the continued results from David A. Dodd, Arban Domi, Mary Hauser, Susan Hensley, MS, RAC, Kelly McKee, Mark Newman, John Niles, Tom O'Brien, Sreenivasa Rao Oruganti, J. Marc Pipas, MD, Erica Raiden, Mark Reynolds, John W. Sharkey, Jeff Welch, Ashley Zuniga, PhD PMP and the entire GeoVax Labs, Inc. team! Thanks to the stellar team at ROTH for organizing this conference: Sagar Sheth, Byron Roth, Isabel Mattson-Pain, Amanda McAdams, Otilia "Charo" Montano, Benjamin Bowen, James Antonopoulos, Jason Wittes, Jonathan Aschoff, Ph.D., Boobalan Pachaiyappan, Ph.D. and many others ROTH is a relationship-driven investment bank headquartered in Newport Beach, CA. For more information on ROTH, please visit roth.com. We hope you’ll be able to attend this pivotal event shaping the future of healthcare innovation.